August 29, 2018
FDA proposes not including three bulk drug substances that outsourcing facilities may use in compounding
Editor's Note
The Food and Drug Administration (FDA) on August 28 issued a notice proposing not to include three bulk FDA-approved drug substances−bumetanide, nicardipine hydrochloride, and vasopressin−on the list that outsourcing facilities may use in compounding drug products.
The FDA is seeking public comment before finalizing their decision. Comments must be received by October 29, 2018.
Free Daily News
- CDC communication breakdown raises public health risk
- Study: Shorter radiation schedule matches safety of standard prostate cancer treatment
- Poll: Healthcare cybersecurity leaders overlook AI-enabled physical security gaps
- ASC improves hospital efficiency, maintains outcomes despite higher-acuity joint replacement patients
- Hospital support staff cuts raise risk of infection, delays in care
- Study: Blocking stress-linked prolactin surge relieves postoperative pain in women
- Report ranks states by nursing opportunity
- Report: Hospitals double down on ASCs as outpatient shift accelerates
- Centralized waitlists slash joint replacement wait times in Canada, study shows
- Airborne bacteria pose hidden threat in cardiac ORs, study warns
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement